Generic Name and Formulations:
Haemophilus b conjugate vaccine (diphtheria CRM197 conjugate) 10mcg capsular oligosaccharides, 25mcg diphtheria CRM197 protein; per 0.5mL dose; IM inj; multidose vials contain thimerosal.
Indications for HIBTITER:
Immunization of children against H. influenza type b.
<2 months: not recommended. At 2, 4, and 6 months: 0.5mL IM. Previously unvaccinated children, 7–11 months: 2 doses of 0.5mL IM 2 months apart. 12–14 months: 0.5mL IM once. All children vaccinated before 15 months of age should receive booster at 15 months (but not less than 2 months after previous shot). 15–60 months: 0.5mL IM once.
Immunodeficiency (HIV infection: see literature). Delay administration in febrile or active infection. Have epinephrine inj (1:1000) available. Protection begins several days after vaccination. Not a substitute for routine diphtheria vaccination. Pregnancy (Cat.C): not recommended.
Local reactions, fever.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Immune Checkpoint Inhibitors for NSCLC: Current and Future Approaches
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Erdafitinib Granted FDA Breakthrough Therapy Designation for Urothelial Carcinoma
- NSCLC: Stratifying Patients With Complex EGFR Mutations
- Nivolumab Plus Ipilimumab Improves Overall Survival, ORR in Renal Cell Carcinoma
- Encorafenib, Binimetinib May Be Effective in BRAF-Mutant Melanoma
- CLL: Venetoclax Plus Rituximab Improves 2-Year PFS
- Confronting Racial Disparities in Prostate Cancer Survival Outcomes
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma